Screening Novel Agent Combinations to Expedite CTCL Therapeutic Development

J Invest Dermatol. 2021 Jan;141(1):217-221. doi: 10.1016/j.jid.2020.05.097. Epub 2020 Jun 12.

Affiliations

¹ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA.
² Yale Center for Molecular Discovery, Yale University, New Haven, Connecticut, USA.
³ Department of Internal Medicine, Section of Medical Oncology, Yale School of Medicine, New Haven, Connecticut, USA.
⁴ Department of Dermatology, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: michael.girardi@yale.edu.

PMID: 32534802
DOI: 10.1016/j.jid.2020.05.097

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Drug Therapy, Combination
Humans
Lymphoma, T-Cell, Cutaneous / drug therapy*
Skin Neoplasms / drug therapy*

Substances

Antineoplastic Agents

Grants and funding

TL1 TR001864/TR/NCATS NIH HHS/United States